ID: ALA3356383

Max Phase: Preclinical

Molecular Formula: C36H39N5

Molecular Weight: 541.74

Molecule Type: Small molecule

Representations

Canonical SMILES:  c1ccc(Nc2cc3nc4ccccc4n(-c4ccccc4)c-3c/c2=N/CCC[C@@H]2CCCN3CCCC[C@H]23)cc1

Standard InChI:  InChI=1S/C36H39N5/c1-3-15-28(16-4-1)38-32-25-33-36(41(29-17-5-2-6-18-29)35-21-8-7-19-30(35)39-33)26-31(32)37-22-11-13-27-14-12-24-40-23-10-9-20-34(27)40/h1-8,15-19,21,25-27,34,38H,9-14,20,22-24H2/b37-31-/t27-,34-/m1/s1

Standard InChI Key:  YLBJZMFDQVANBC-NVOLYDOPSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 541.74

Molecular Weight (Monoisotopic): 541.3205

AlogP: 7.82

#Rotatable Bonds: 7

Polar Surface Area: 45.45

Molecular Species: BASE

HBA: 5

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 9.53

CX LogP: 7.61

CX LogD: 4.98

Aromatic Rings: 3

Heavy Atoms: 41

QED Weighted: 0.17

Np Likeness Score: -0.44

References

1. Barteselli A, Casagrande M, Basilico N, Parapini S, Rusconi CM, Tonelli M, Boido V, Taramelli D, Sparatore F, Sparatore A..  (2015)  Clofazimine analogs with antileishmanial and antiplasmodial activity.,  23  (1): [PMID:25497962] [10.1016/j.bmc.2014.11.028]

2. Tonelli M, Novelli F, Tasso B, Sparatore A, Boido V, Sparatore F, Cannas S, Molicotti P, Zanetti S, Parapini S, Loddo R..  (2014)  Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.,  22  (24): [PMID:25464882] [10.1016/j.bmc.2014.10.035]

Source

Source(1):

• Scientific Literature